Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer
Journal of Robotic Surgery · 2022-04 · 16 (2) · 369-375
DOI: 10.1007/s11701-021-01252-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Robotic Surgery, online erschienen am 12.05.2021. Verfasst von G J Nason und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada. Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Robotic Surgical Procedures, Testicular Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The role of retroperitoneal lymph node dissection (RPLND) in testicular cancer is well established in both the primary and post-chemotherapy setting. The aim of this study was to report our 2 years oncological outcomes of robotic RPLND. A retrospective review was performed of all patients undergoing robotic RPLND by a single surgeon at Princess Margaret Cancer Centre. Demographic, perioperative, and oncologic data were analyzed using descriptive statistics. Between September 2014 and June 2020, 141 patients underwent an RPLND [33 (23.4%) were primary, 108 (76.6%) were post-chemotherapy]. 27 (19.1%) patients underwent a robotic bilateral template nerve-sparing RPLND. RPLND indication was primary (i.e. pre-chemotherapy) in 18 (66.7%), and post-chemotherapy in 9 (33.3%) patients. Stage at RPLND was 2A (n = 15, 55.6%), 2B (n = 9, 33.3%), 2C (n = 1, 3.7%) and 3 (n = 2, 7.4%). Median OR time (incision to closure) was 525 min and blood loss was 200 ml. Nerve sparing was performed in all but one case. Six (22.2%) adjuvant procedures were performed including two (7.4%) vascular repairs. Median length of stay was 2 days. Viable tumor was detected in 17 (63%) and teratoma in 9 (33.3%). Median follow-up was 31.3 months. No adjuvant chemotherapy was given. Three patients (11.1%) relapsed: 2 out-of-field and 1 with both in-field and out-of-field disease. Robotic RPLND can be performed safely. Long-term follow-up of series such as ours, enriched with patients with viable disease and/or teratoma, and not treated with adjuvant chemotherapy is required to ensure oncological outcomes are comparable to the open approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada.
- Division of Abdominal Imaging, Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada.
- Department of Pathology and Lab Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada. rob.hamilton@uhn.ca.
Zitieren
APA
Nason, G. J., Kuhathaas, K., Anson-Cartwright, L., Jewett, M. A. S., O'Malley, M., Sweet, J., Hansen, A., Bedard, P., Chung, P., Hahn, E., Warde, P., & Hamilton, R. J. (2022). Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer. Journal of Robotic Surgery, 16(2), 369-375. https://doi.org/10.1007/s11701-021-01252-1
Vancouver
Nason GJ, Kuhathaas K, Anson-Cartwright L, Jewett MAS, O'Malley M, Sweet J, et al. Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer. Journal of Robotic Surgery. 2022;16(2):369-375. doi:10.1007/s11701-021-01252-1
BibTeX
@article{Nason2022,
author = {Nason, G J and Kuhathaas, K and Anson-Cartwright, L and Jewett, M A S and O'Malley, M and Sweet, J and Hansen, A and Bedard, P and Chung, P and Hahn, E and Warde, P and Hamilton, R J},
title = {Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer},
journal = {Journal of Robotic Surgery},
year = {2022},
volume = {16},
number = {2},
pages = {369--375},
doi = {10.1007/s11701-021-01252-1}
}
EUVIMED